Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q1 2023 Results Conference Call May 9, 2023 8:30 AM ET

Company Participants

Pete Pfreundschuh - Chief Financial Officer

Dr. Al Sandrock - Chief Executive Officer

Dr. Todd Carter - Chief Scientific Officer

Conference Call Participants

Jay Olson - Oppenheimer

Jack Allen - Baird

Philip Nadeau - TD Cowen

Yanan Zhu - Wells Fargo

Laura Chico - Wedbush

Joon Lee - Truist Securities

Sumant Kulkarni - Canaccord

Operator

Good morning and welcome to Voyager Therapeutics First Quarter 2023 Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the end of the call. Please be advised this call is being recorded at the Company's request. A replay of today’s call will be available on the Investor section of the Company’s website approximately 2 hours after completion of this call.

I would now like to turn the call over to Pete Pfreundschuh, Chief Financial Officer. Please go ahead.

Pete Pfreundschuh

Thank you and good morning. Joining me on today's call are Dr. Al Sandrock, our CEO; Dr. Todd Carter, our Chief Scientific Officer. We issued our Q1 2023 financial results press release this morning. The press release and 10-K are available on our website. We plan to provide a brief summary of key highlights from the quarter and reserve the majority of time for your Q&A.

In a moment, I will turn the call over to Al. Before I do this, I want to remind everyone that during this call, Voyager representatives may make forward-looking statements, as noted in Slide 2 of today's desk. These forward-looking statements include future expectations, plans and prospects. All forward-looking statements are inherently uncertain and are subject to risks and uncertainties that may cause actual results to differ materially from those indicated by these forward-looking statements. You are encouraged to review and understand various material risks and uncertainties facing the Company as described in the Company's annual report on Form 10-K filed with the SEC. As in the filing of today's quarterly report on Form 10-Q, there have been no material changes to the risk factors described in our annual report. All SEC filings are available on the Company's website.

Now, it is my pleasure to turn the call over to Al.

Dr. Al Sandrock

Thank you, Pete, and good morning, everyone. Please turn to Slide 3. I'd like to take a moment to recognize the incredible innovation happening right now in neurotherapeutics and in gene therapy. We believe we are witnessing a renaissance in neurotherapeutics. Just this year, the second disease modifying therapy for Alzheimer's disease received accelerated approval and the first drug was approved for Friedreich's ataxia. We have seen breakthroughs in treating negative symptoms of schizophrenia, something for which there are no approved therapies.